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Abstract We have characterised L-lactate transport in rat
adipocytes and determined whether these cells express a carrier
belonging to the monocarboxylate transporter family. L-Lactate
was taken up by adipocytes in a time-dependent, non-saturable
manner and was inhibited (by V90%) by K-cyano-4-hydroxy-
cinnamate. Lactate transport was stimulated by 3.7-fold upon
lowering extracellular pH from 7.5 to 6.5 suggesting the presence
of a lactate/proton-cotransporter. Antibodies against mono
carboxylate transporter 1 (MCT1) reacted positively with
plasma membranes (PM), but not with intracellular membranes,
prepared from adipocytes. MCT1 expression was down-regu-
lated in PM of adipocytes from diabetic rats, which also
displayed a corresponding loss (V64%) in their capacity to
transport lactate. The data support a role for MCT1 in lactate
transport and suggest that changes in MCT1 expression are
likely to have important implications for adipocyte lactate
metabolism. ß 2000 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
In mammalian cells the production of lactic acid represents
one of the key end-points of glucose metabolism which con-
tributes signi¢cantly towards acidi¢cation of the intracellular
compartment. To help maintain intracellular acid^base ho-
meostasis and metabolic control, monocarboxylates such as
lactate and pyruvate are transported across the plasma mem-
brane (PM) by a family of monocarboxylate/H co-transport-
ers (MCT) [1]. There are several isoforms of MCT transport-
ers that mediate the transfer of unbranched aliphatic
monocarboxylates from C-2 to C-5 (e.g. lactate, C-3) across
the PM of mammalian cells. This group of transporters in-
cludes the Na-dependent monocarboxylate transporters,
which are predominantly expressed in intestinal and renal
epithelia where they function primarily to aid reabsorption
of lactate, pyruvate and ketone bodies [2]. To date, eight
members of the MCT family have been characterised, denoted
as MCT1^7 and XPCT (MCT8) which are expressed in a
tissue-dependent manner possibly re£ecting distinct functional
roles [1,3,4]. For example, skeletal muscle, a tissue that not
only generates large quantities of lactate but one that may
also utilise it as a respiratory fuel, expresses MCT1 and
MCT4. Expression of both isoforms in this tissue can be rap-
idly modulated in response to changes in muscular activity
suggesting that the turnover of MCT proteins in this tissue
may be closely regulated by rates of lactate production, a
feature that may be important in helping to regulate intra-
muscular pH [4].
In addition to its lipogenic and lipolytic functions, adipose
tissue is also an important site of lactate production [5]. The
overall contribution made by adipose tissue to whole body
lactate production can, however, vary considerably depending
on the percentage of body fat. In lean individuals, for exam-
ple, white fat constitutes between 15 and 25% of body mass,
whereas in severely obese subjects it may account for as much
as 50% of total body mass [6]. Lactate production in adipose
tissue is known to be modulated by altered pathology. During
insulin lack or insulin resistance, when there is a marked re-
duction in total glucose metabolism, there is an associated fall
in whole body lactate production [7]. In contrast, lactate pro-
duction is signi¢cantly enhanced, accounting for between 45
and 70% of the total glucose metabolised, during obesity when
fat cells undergo enlargement and also during fasting [8^10].
Indeed, it is has been suggested that lactate over-production
associated with fat cell enlargement may be a factor that con-
tributes to many of the abnormalities that accompany the
development of obesity and carbohydrate intolerance [5]. Sur-
prisingly, however, despite the important role played by adi-
pose tissue in the regulation of whole-body lactate dynamics
very little is known about the mechanism by which lactate is
transported across the fat cell membrane and whether this
process is modulated by disease states, such as diabetes. In
the present study we have characterised L-lactate transport in
rat adipocytes and show, for the ¢rst time, that this tissue
expresses MCT1, a member of the monocarboxylate trans-
porter family. We also show that this transporter localises
speci¢cally to the PM of the adipocyte and that its expression
is down-regulated during streptozotocin (STZ)-induced diabe-
tes leading to an associated reduction in lactate transport.
2. Materials and methods
2.1. Reagents and animals
All chemicals were purchased from Sigma unless indicated other-
wise in the text. Male Sprague Dawley rats (V250 g, Bantin and
Kingman, Hull, UK) were killed by cervical dislocation and epididy-
mal fat-pads removed. Adipocytes were isolated from these by colla-
genase digestion as described previously [11]. In some experiments,
rats were made diabetic by a single subcutaneous injection of 65
mg/kg anhydrous STZ (Sigma) reconstituted in citrate-bu¡ered saline
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(pH 4.5). Control animals were injected with vehicle alone. Urine
samples were taken daily to assess diabetic status using Ladstix strips
for urine glucose (Bayer Diagnostics) and blood was sampled at the
time of killing for analysis of glucose using Glucostix strips (Bayer
Diagnostics). Urine of diabetic animals reacted positively for the pres-
ence of glucose and blood glucose was typically in excess of 15 mmol/
l. Rats were maintained diabetic for a period of 4 days after which
period they were killed for adipocyte harvest.
2.2. Lactate uptake in adipocytes
Isolated rat adipocytes were incubated in Krebs bu¡er (KRP bu¡er,
120 mM NaCl; 4.8 mM KCl; 1.3 mM CaCl2 ; 1.2 mM MgSO4 ; 3.1
mM NaH2PO4 ; 12.5 mM Na2HPO4 ; 200 nM adenosine; 2% bovine
serum albumin (w/v, fraction V); pH 7.4) in the absence or presence
of inhibitors, if indicated. Uptake was started by addition of
L-[14C(U)]lactate (NEN, Boston, MA, USA, speci¢c activity 174.6
mCi/mmol) and [3H]inulin (NEN, speci¢c activity 0.63 mCi/mmol)
which was used to measure non-speci¢c cell-associated radioactivity.
Uptake was terminated after 10 min by rapid centrifugation through a
100 Wl di-isononyl phtalate oil cushion (Fluka, Gillingham, Dorset,
UK) for 20 s and samples processed for liquid scintillation counting
using a dual channel program.
2.3. Western blot analysis
PMs and low density microsomes (LDMs) from adipose tissue were
prepared as described previously [11,12]. Isolated membrane fractions
were subjected to SDS^PAGE on 10% polyacrylamide gels as de-
scribed by Laemmli [13], and electrophoretically transferred onto ni-
trocellulose membranes. Membranes were incubated with speci¢c
polyclonal antibodies against MCT1 or MCT4 (both 1:200, kindly
provided by Professor A.P. Halestrap, University of Bristol, UK).
Membranes were also immunoblotted with antibodies against
GLUT4 (1:500, East Acres, Southbridge, MA, USA), or against rat
GLUT5 (1:1000, generously provided by Dr Y. Oka, Japan, [14]).
Primary detection was carried out using horseradish peroxidase-con-
jugated secondary antibody (1:1000, HRP anti-rabbit IgG, SAPU,
UK). Immunoreactive bands were detected by the enhanced chemilu-
minescence method (Amersham, Life Science, Bucks, UK).
2.4. Statistical analysis
Statistical analyses were carried out using a two-tailed Student’s
t-test, data were considered signi¢cant at P values less than 0.05.
3. Results and discussion
3.1. L-Lactate uptake in rat adipocytes
We ¢rst assessed whether isolated rat adipocytes possessed
the capacity to transport L-lactate. Fig. 1A shows that uptake
of 50 WM L-lactate was linear for up to 30 min. After this
period uptake became non-linear approaching equilibrium by
approximately 2 h of incubation. Based on this observation all
subsequent experiments were performed over 10 min for con-
venience. To assess the kinetics of lactate transport in isolated
adipocytes, cells were incubated in the presence of increasing
concentrations of unlabelled L-lactate (from 50 WM to 50
mM). Lactate uptake was found to be not saturable over
the range of concentrations used possibly suggesting that lac-
tate is either transported passively across the PM of adipo-
cytes or that it is taken up by a very low a⁄nity high capacity
transporter or channel. This ¢nding is di¡erent to that re-
ported for other insulin responsive tissues, such as heart and
skeletal muscle, in which uptake of lactate has been shown to
be a saturable process [15^17].
3.2. E¡ect of K-cyano-4-hydroxycinnamate (CHC) on
L-lactate uptake
In order to better characterise the process by which lactate
was taken up into rat adipocytes, we pre-incubated isolated
fat cells for 10 min with 5 mM CHC, a well-established in-
hibitor of L-lactate uptake [1]. Fig. 2 shows that CHC sup-
pressed L-lactate uptake byV90% (P6 0.001). This inhibition
could not be prevented by increasing concentrations of L-lac-
tate suggesting that CHC either acts in a non-competitive
fashion or that the highest concentration of lactate used was
insu⁄cient to compete out or reverse the inhibition exerted by
CHC. If the latter were so, this would imply that the transport
process has a much higher a⁄nity for CHC than lactate. This
latter possibility cannot be excluded given our inability to
saturate L-lactate transport at lactate concentrations as high
as 50 mM and reports in the literature indicating that the IC50
for CHC inhibition of the monocarboxylate transporter is
V27 WM [2]. CHC is thought to act by binding to the high
a⁄nity internal substrate binding site of the monocarboxylate
transporter. Thus the substantial inhibition in L-lactate uptake
seen in the presence of CHC would support the presence of a
membrane bound lactate carrier and suggests that passive
movement of lactate across the adipocyte PM is likely to
make only a minor contribution towards lactate transport.
3.3. E¡ect of extracellular pH upon L-lactate uptake
Fig. 3 shows that the initial rate of L-lactate uptake was
markedly dependent on the extracellular pH. The initial rate
Fig. 1. Time course of L-lactate uptake and the e¡ects of extracellu-
lar L-lactate concentration on L-lactate uptake in isolated rat adipo-
cytes. A: The uptake of L-lactate (50 WM) in rat adipocytes was as-
sayed as described in Section 2 for the times indicated. B: Isolated
rat adipocytes were incubated in the presence of di¡erent concentra-
tions of unlabelled L-lactate and uptake of radiolabelled lactate de-
termined over 10 min as described in Section 2. Values represent
the mean þ S.E.M. for up to nine separate experiments, each per-
formed in triplicate.
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of lactate uptake at 50 WM was 3.7-fold higher at pH 6.5
compared to that assayed in cells maintained in uptake bu¡er
at pH 7.4. These observations are in line with that reported in
other cell types showing that transfer of lactate across the PM
involves the cotransport of lactate and a proton [1]. Although
it is widely accepted that the Na/H antiporter is the major
regulator of intracellular pH [18], the coupled movement of
lactate and protons is also likely to make an important con-
tribution towards removal of metabolically produced acid in
adipose tissue.
3.4. Expression and subcellular distribution of MCT1 in rat
adipocytes
The results presented thus far support the presence of a
lactate transport protein that is not readily saturated, but
which is sensitive to inhibition by CHC and whose activity
is enhanced by low extracellular pH. To establish the identity
and localisation of the carrier(s), we performed subcellular-
fractionation of rat adipocytes to isolate PMs and LDMs
(internal membranes). Membrane protein was subjected to
SDS^PAGE and immunoblotted with antibodies against two
monocarboxylate transporters (MCT1 and MCT4) both of
which are expressed in skeletal muscle, another primary insu-
lin target tissue. PM and LDM were also probed with anti-
bodies against the insulin responsive glucose transporter,
GLUT4, and the GLUT5 fructose transporter as appropriate
marker proteins. In adipocytes that have not been stimulated
with insulin, the majority of the GLUT4 is localised intracell-
ularly within specialised storage vesicles that are present in the
LDM fraction [19], whereas GLUT5 is expressed only in the
PM of rat adipocytes [11]. Consistent with this, expression of
GLUT5 and GLUT4 protein was largely restricted to the PM
and LDM fractions, respectively (Fig. 4A). When these mem-
Fig. 2. E¡ect of CHC on L-lactate uptake in isolated rat adipocytes.
Cells were pre-incubated in the absence or presence of 5 mM CHC
for 10 min prior to assaying L-lactate uptake at di¡erent extracellu-
lar concentrations of unlabelled L-lactate as described in the Section
2. Values represent the mean þ S.E.M. for three to nine separate ex-
periments each performed in triplicate.
Fig. 3. E¡ect of extracellular pH on L-lactate uptake in isolated rat
adipocytes. Isolated adipocytes were washed twice with KRP bu¡er
(pH of the bu¡er was adjusted to that required and cell washes
lasted no longer than 2 min) prior to assaying uptake of 50 WM
L-lactate at the desired pH as described in Section 2. Values are
means þ S.E.M. of three separate experiments performed in tripli-
cate.
Fig. 4. Representative Western Blots showing the abundance of
GLUT5, GLUT4 and MCT1 in rat adipocyte membranes, crude
membranes from rat brain and liver and the e¡ects of STZ-diabetes
on MCT1 expression in rat adipocytes. A: PMs (1), LDMs (2),
brain (3) and liver (4) crude membranes (35 Wg of each) were ap-
plied to SDS^PAGE gels and immunoblotted using isoform-speci¢c
antibodies against GLUT4, GLUT5 and MCT1 as described in Sec-
tion 2. B: Rats were rendered diabetic with STZ. PMs and low den-
sity membranes (LDM) were prepared by subcellular fractionation
of isolated adipocytes and subjected to SDS-PAGE and immuno-
blotting as described in Section 2. Representative immunoblot show-
ing MCT1 expression in control (C) and diabetic (STZ) rats in PM
and LDM fractions. C: Densitometric quanti¢cation of MCT1
abundance in adipocyte PM from diabetic rats. MCT1 signal den-
sities from control animals were assigned a value of 100%. Values
represents means þ S.E.M. (n = 3). *Statistically signi¢cant change
(P6 0.05, Student’s t-test).
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brane fractions were probed with an antibody to MCT1 a
single 43 kDa immunoreactive band, which comigrated with
that detected in rat liver membranes, was observed in the PM
fraction. A much weaker signal was also observed in the
LDM and most likely re£ected a small degree of contamina-
tion of the LDM fraction with PM as, unlike the PM signal,
this weaker signal was not consistently observed in di¡erent
LDM preparations (e.g. see Fig. 4B). When PM and LDM
fractions were subsequently probed with an antibody to
MCT4 we were unable to detect the presence of this MCT
isoform in adipocyte membranes. It is noteworthy, however,
that the MCT4 antibody did react positively with a protein of
the appropriate molecular size in membranes prepared from
rat skeletal muscle (data not shown) indicating that the ab-
sence of this carrier in fat cell membranes was not due to
problems associated with antibody speci¢city.
Since lactate is a major product of glucose metabolism and
the utilisation of glucose is known to be impaired in insulin
responsive tissues during diabetes we investigated whether ex-
pression of MCT1 and lactate uptake in adipocytes could be
modulated in animals rendered diabetic by STZ treatment.
Fig. 4B shows that a 4 day period of STZ-induced diabetes
caused a marked reduction in MCT1 expression. We found
that MCT1 abundance in the PM fraction of diabetic rat
adipocytes fell by approximately 80% (Fig. 4C). In line with
the observed fall in MCT1 expression, lactate uptake in adi-
pocytes isolated from diabetic rats also fell by 64% from
1.45 þ 0.31 nmol/min/1000 cells. We currently do not know
whether insulin lack itself has a direct e¡ect on MCT1 gene
expression or if the fall in MCT1 protein is a consequence of
diminished glycolytic metabolism. Previous work has shown
that, in absolute terms, adipocytes isolated from lean diabetic
rats produce signi¢cantly less lactate from glucose when com-
pared with fat cells from lean controls [7]. It is thus conceiv-
able that the amount of lactate produced may act as a signal
that regulates the expression of its membrane transport pro-
tein. This possibility is supported by studies showing that
increased muscular activity (and hence increased lactate pro-
duction) enhances muscle MCT1 expression [20,21], whereas
as muscle inactivity, as a result of muscle denervation, pro-
motes a fall in MCT1 expression [21]. The ability of substrates
to regulate the expression of their own carrier proteins is not
unprecedented. We, and others, have shown, for example, that
increased dietary intake of fructose induces a signi¢cant in-
crease in jejunal and renal expression of the GLUT5 fructose
transporter in rats [22,23]. The enhanced expression of
GLUT5 in both of these tissues is likely to be of physiological
importance as it will enable greater intestinal absorption and
renal reabsorption of fructose. Whether changes in lactate
production also elicit similar e¡ects on MCT expression in
adipocytes is currently unknown, but if it does, it raises im-
portant questions concerning how cells sense changes in lac-
tate availability and the mechanisms used to signal changes in
MCT expression.
In summary, we have shown that the PM of adipocytes
express the MCT1 transporter which, we believe, is likely to
represent the principal route for lactate transport across the
fat cell membrane. Our data indicate that uptake of L-lactate
in adipocytes is not saturable, but is acutely stimulated by a
fall in extracellular pH and is inhibited substantially by CHC,
a classical inhibitor of lactate transport. MCT1 expression is
down-regulated in adipose tissue during diabetes possibly re-
£ecting that the reduced conversion of glucose to lactate
which prevails during the diabetic state may serve to regulate
the ‘turnover’ of this monocarboxylate transporter. Given the
importance of adipose tissue in whole body lactate metabo-
lism it is likely that MCT1 acts as a key intermediary in
shuttling lactate to tissues such as liver where it may be
used for hepatic gluconeogenesis during fasting and perhaps
glycogen synthesis in the post-absorptive state.
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